Paradigm Biopharmaceuticals Limited (ASX:PAR – Get Free Report) insider Paul Rennie acquired 5,181,688 shares of the stock in a transaction on Tuesday, February 11th. The stock was bought at an average price of A$0.50 ($0.32) per share, with a total value of A$2,590,844.00 ($1,639,774.68).
Paradigm Biopharmaceuticals Price Performance
The stock has a market capitalization of $196.66 million, a PE ratio of -2.47 and a beta of 0.94. The company has a quick ratio of 5.93, a current ratio of 7.22 and a debt-to-equity ratio of 1.01.
About Paradigm Biopharmaceuticals
Further Reading
- Five stocks we like better than Paradigm Biopharmaceuticals
- Trading Stocks: RSI and Why it’s Useful
- Nebius Group: NVIDIA’s Investment Sparks All-Time Highs
- How to Find Undervalued Stocks
- SoFi Stock Rallying Strong in the Last 5 Days—What’s Driving It?
- What is the Shanghai Stock Exchange Composite Index?
- Intel Surges on M&A Talks: Rally Beginning or Just a Headfake?
Receive News & Ratings for Paradigm Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paradigm Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.